Status Epilepticus: 6 Updated Practice Considerations
Evidence synthesis on stepwise treatment of status epilepticus — ESETT second-line agent comparison, ketamine for refractory disease, and NCS/AES protocol-driven care.
One-Minute Takeaway on Status Epilepticus
One-Minute Takeaway
- Strong evidence supports a time-defined stepwise approach to status epilepticus, beginning with adequate-dose benzodiazepines within the first 5–20 minutes and escalating through second-line and anesthetic phases at predefined intervals.
- The ESETT trial demonstrated equivalent efficacy of fosphenytoin, valproate, and levetiracetam as second-line agents, with seizure cessation achieved in approximately 45–47% across all three arms.
- Refractory disease — failure of benzodiazepine plus second-line agent — requires anesthetic infusion (midazolam, propofol, or pentobarbital) with continuous EEG monitoring in the intensive care unit.
- Ketamine has emerging evidence as an adjunct in refractory and super-refractory status epilepticus, supported by case series and a growing observational dataset rather than randomized trials.
- Mortality remains 15–25% overall and rises to 40–60% in super-refractory disease despite optimal management — etiology drives outcome more than choice of antiseizure agent.
Why This Topic Matters
Status epilepticus is the most common neurological emergency after stroke, with an estimated incidence of 10–40 per 100,000 person-years. Convulsive status epilepticus carries a short-term mortality of approximately 20% in adults, rising sharply once seizures persist beyond the second-line treatment phase.
Time is the dominant prognostic variable. Each additional minute of ongoing seizure activity reduces the probability of pharmacologic seizure cessation, increases neuronal injury, and raises the risk of progression to refractory and super-refractory disease.
Despite this urgency, real-world practice diverges substantially from guideline-recommended protocols. Audits consistently show under-dosing of benzodiazepines, delays in administering second-line agents, and inconsistent escalation to anesthetic infusion. Closing these gaps is the single highest-yield improvement available to most institutions.
The 2019 ESETT trial fundamentally reshaped the second-line conversation by demonstrating that fosphenytoin, valproate, and levetiracetam are equivalent in efficacy. The 2016 AES guideline and 2012 NCS guidelines remain foundational, while ketamine and emerging immunomodulatory approaches are being studied for refractory disease.
For neurologists and emergency physicians, the practical question is no longer which agent to choose but how reliably to deliver the right agent at the right dose at the right time. Evidence-aligned management depends as much on systems and protocols as on pharmacology.
What Evidence Was Reviewed
This evidence synthesis draws on the foundational 1998 VA Cooperative trial, the 2001 out-of-hospital comparison, the 2012 RAMPART trial, the 2019 ESETT trial, the AES and NCS practice guidelines, the ILAE classification, and the major observational evidence base for ketamine in refractory disease.
Inclusion focused on adult convulsive status epilepticus, with extrapolation to pediatric data noted where relevant. Primary outcomes across trials were seizure cessation within a defined time window, recurrence within 12–24 hours, and short-term mortality.
| Source | Type | n | Comparison | Headline finding |
|---|---|---|---|---|
| ESETT (Kapur et al., NEJM 2019) | RCT | 384 | Fosphenytoin vs valproate vs levetiracetam (post-benzo) | Seizure cessation 45–47% across all three arms; Bayesian equivalence |
| RAMPART (Silbergleit et al., NEJM 2012) | RCT (pre-hospital) | 893 | IM midazolam vs IV lorazepam | IM midazolam non-inferior; faster administration; 73% vs 63% cessation |
| VA Cooperative (Treiman et al., NEJM 1998) | RCT | 518 | Lorazepam vs diazepam+phenytoin vs phenobarbital vs phenytoin | Lorazepam most effective first-line agent; phenytoin alone least effective |
| Alldredge 2001 (NEJM) | RCT (out-of-hospital) | 205 | Lorazepam vs diazepam vs placebo (paramedic-administered) | Both benzodiazepines superior to placebo; lorazepam numerically better |
| AES Guideline (Glauser et al., 2016) | Practice guideline | Narrative synthesis | Time-defined phases; first-, second-, third-line agents | Stepwise protocol with adequate benzo dosing emphasized |
| NCS Guidelines (Brophy et al., 2012) | Practice guideline | Narrative synthesis | ICU-level management of refractory disease | Anesthetic infusion with continuous EEG; treat to electrographic suppression |
| Trinka 2015 (Epilepsia, ILAE) | Classification | — | Operational definition of status epilepticus | 5-min and 30-min thresholds (t1 and t2) for definition and prognosis |
| Gaspard 2013 (Epilepsia) | Multicenter retrospective | 58 | IV ketamine in refractory status epilepticus | Seizure cessation in ~57%; case-series-level evidence |
| Rosati 2012 (Neurology) | Pediatric series | 9 | Ketamine in refractory pediatric status epilepticus | Cessation in 8/9; supportive observational signal |
| Hocker 2013 (JAMA Neurol) | Cohort | 63 | Predictors of outcome in refractory disease | Acute symptomatic etiology and age over 50 predicted poor outcome |
| Shorvon & Ferlisi 2011 (Brain) | Critical review | Narrative | Super-refractory status epilepticus therapies | Synthesizes anesthetic, immunomodulatory, surgical options |
Key Findings on Status Epilepticus Treatment
Theme 1: ESETT establishes equivalence among second-line agents
The ESETT trial enrolled 384 patients whose seizures failed to respond to adequate benzodiazepine and randomized them to fosphenytoin, valproate, or levetiracetam. Bayesian analysis showed near-identical efficacy across the three arms.
Seizure cessation and improved responsiveness within 60 minutes occurred in 45% of fosphenytoin recipients, 46% of valproate recipients, and 47% of levetiracetam recipients. Adverse events — including life-threatening hypotension and intubation — were also similar across arms.
The clinical implication is that second-line agent choice should be driven by patient-specific factors: hepatic function, drug interactions, infusion-rate tolerance, and local availability rather than presumed potency. ESETT removed efficacy from that equation.
Theme 2: Adequate benzodiazepine dosing is the most underused intervention
The RAMPART trial confirmed intramuscular midazolam 10 mg as non-inferior to intravenous lorazepam 4 mg in the pre-hospital setting, with seizure cessation rates of 73% versus 63%. The Alldredge 2001 trial similarly demonstrated benzodiazepine superiority over placebo with paramedic administration.
Real-world audits across academic centers consistently show under-dosing — single 1–2 mg lorazepam doses for adults are common despite guideline recommendations of 0.1 mg/kg up to 4 mg per dose, repeated once at 5 minutes. Failure to deliver adequate benzodiazepines is the single most preventable cause of progression to refractory disease.
Theme 3: Time-defined phases anchor practical protocols
The 2015 ILAE operational definition codified two time thresholds — t1 (continuous activity beyond which a seizure is unlikely to stop spontaneously) and t2 (continuous activity beyond which long-term consequences become likely). For convulsive disease these are 5 and 30 minutes respectively.
The AES guideline organizes care into time windows: 0–5 minutes for stabilization, 5–20 minutes for benzodiazepine, 20–40 minutes for second-line, and 40+ minutes for anesthetic infusion. These windows now form the backbone of most institutional protocols.
Theme 4: Anesthetic infusion is the standard for refractory disease
Once benzodiazepine and a second-line agent have failed, NCS guidelines recommend anesthetic infusion in the intensive care unit with continuous EEG monitoring. Common choices are midazolam, propofol, and pentobarbital, titrated to either electrographic seizure suppression or burst suppression.
No randomized trial directly compares these agents head-to-head. The choice typically reflects local familiarity, hemodynamic considerations, and ICU resources. Continuous EEG is essential because clinical signs of seizure activity often disappear under sedation while electrographic seizures persist — a phenomenon that meaningfully changes management.
Theme 5: Ketamine has growing evidence as a refractory adjunct
Ketamine acts at the NMDA receptor, complementing the GABAergic mechanism of benzodiazepines and most anesthetics. In progressively refractory disease, GABA-A receptors internalize and become less responsive, providing biological rationale for adding an NMDA antagonist.
The Gaspard 2013 multicenter retrospective study of 58 adults with refractory disease reported permanent seizure cessation in approximately 57% after ketamine initiation. Pediatric series including Rosati 2012 reinforce the signal but the evidence remains observational. Randomized data are emerging but not yet sufficient to elevate ketamine to first-line refractory therapy.
Theme 6: Etiology drives outcome more than agent selection
Across cohorts including the Hocker 2013 series, the dominant predictors of mortality and disability are acute symptomatic etiology — particularly anoxic brain injury and severe CNS infections — and older age. Choice of second-line agent has not been shown to alter mortality.
This pattern reframes management goals. Rapid seizure cessation matters for neuronal injury and for preventing progression to refractory disease, but the overall trajectory of the patient is largely determined by the underlying cause. Concurrent investigation and treatment of the precipitating illness are inseparable from seizure-directed therapy.
Clinical pearl. Two questions reliably separate well-managed cases from poorly managed ones: was the benzodiazepine dose adequate (0.1 mg/kg lorazepam IV or 10 mg IM midazolam) and was the second-line agent given within 20 minutes of recognition? Most preventable progressions to refractory disease occur when one of these is missed.
Quality & Consistency of Evidence
The evidence base for convulsive seizures requiring emergency treatment is anchored by four major randomized trials spanning 1998–2019 and reinforced by detailed practice guidelines. Refractory and super-refractory phases are dominated by observational data because randomized trials in critically ill seizing patients are operationally and ethically difficult.
What the Evidence Does Not Show
Despite substantial randomized evidence for the early phases, several important questions remain unanswered. These gaps justify cautious framing of recommendations beyond the populations and phases studied.
Specific Gaps in the Evidence Base
- Optimal anesthetic agent in refractory status epilepticus. No randomized comparison of midazolam, propofol, and pentobarbital exists; choice remains practice-pattern-driven.
- Treatment depth (suppression vs burst suppression). Whether deeper EEG suppression improves outcome over electrographic seizure cessation alone is not randomized.
- Ketamine timing and dosing. Optimal timing of ketamine introduction, target dose, and combination with other anesthetics remain undefined by randomized data.
- Non-convulsive status epilepticus in coma. Whether aggressive management improves outcomes in critically ill comatose patients with electrographic seizures only remains debated.
- Therapeutic hypothermia. The HYBERNATUS trial did not show benefit in convulsive disease; role in super-refractory cases remains uncertain.
- Newer agents. Brivaracetam, lacosamide, and topiramate as second- or third-line options have promising observational data but lack RCT-level evidence in this indication.
These gaps justify multidisciplinary, individualized care once status epilepticus progresses beyond the second-line phase. Neurology, critical care, and continuous EEG expertise should converge for refractory and super-refractory disease.
Practical Implications for Status Epilepticus
Based on the current evidence, the following considerations emerge for managing convulsive status epilepticus across the time-defined phases. They reframe what the trial data support — not what individual clinicians must do — and depend on local protocols.
Stabilization Phase (0–5 minutes)
Airway, breathing, circulation, IV access, glucose check, and history-gathering. Most pre-hospital presentations enter the emergency department already past this window.
First-Line Phase (5–20 minutes)
Adequate benzodiazepine: lorazepam 0.1 mg/kg IV (max 4 mg per dose, may repeat once); IM midazolam 10 mg if no IV access; diazepam 0.15 mg/kg IV as alternative. Inadequate first-dose benzodiazepine is the single most common preventable error.
Second-Line Phase (20–40 minutes)
ESETT-validated agents — fosphenytoin 20 mg PE/kg, valproate 40 mg/kg, or levetiracetam 60 mg/kg. Selection driven by patient comorbidities (avoid valproate in hepatic dysfunction; consider fosphenytoin in cardiac patients with caution; levetiracetam often the simplest default).
Refractory Phase (40+ minutes)
Anesthetic infusion in ICU with continuous EEG monitoring: midazolam, propofol, or pentobarbital titrated to electrographic seizure cessation or burst suppression. Maintain for 24–48 hours before tapering.
Super-Refractory Phase (>24 hours of anesthetic)
Add ketamine (loading dose followed by continuous infusion); consider immunotherapy if autoimmune etiology suspected; ketogenic diet, therapeutic hypothermia, and neurosurgical evaluation are case-by-case considerations.
Evidence Supports Adequate-Dose Benzodiazepines
RAMPART, VA Cooperative, and Alldredge consistently show benzodiazepine efficacy when administered at recommended doses; under-dosing is the most common preventable failure point.
Second-Line Agents Show Equivalent Efficacy
ESETT provides high-quality evidence that fosphenytoin, valproate, and levetiracetam are interchangeable; selection should be driven by patient-specific factors.
Continuous EEG Shows Critical Value
Once anesthetics are initiated, clinical seizure signs may abate while electrographic seizures persist; continuous EEG is recommended to guide therapy depth and duration.
Ketamine Shows Promise in Refractory Disease
Observational evidence supports adding ketamine in refractory and super-refractory cases, particularly when GABAergic agents alone have failed.
Implementation Considerations
An institutional status epilepticus protocol — printed, pocket-sized, embedded in the EHR order set, and reinforced by simulation training — produces more reliable improvements in care than individual education alone. Pre-mixed benzodiazepine doses, default order sets for each treatment phase, and dedicated continuous EEG availability are the system-level elements most consistently associated with timely, guideline-aligned management.
Suspect non-convulsive status epilepticus in any unexplained altered consciousness or coma, particularly after cardiac arrest, in the post-ictal patient who fails to recover, or after an apparent successful seizure cessation when responsiveness does not improve. Continuous EEG within 60 minutes of suspicion is the standard diagnostic step.
Most protocols maintain anesthetic infusion for 24–48 hours after electrographic seizure cessation before attempting taper. Premature tapering increases the risk of seizure recurrence. Patients who relapse during taper typically require return to anesthetic depth and a longer maintenance period before the next attempt.
Consider autoimmune encephalitis in unexplained refractory status epilepticus, especially in younger patients with prodromal psychiatric symptoms, prior viral illness, or new-onset disease. Anti-NMDA receptor antibodies and other paraneoplastic markers should be sent early; empiric steroids and IVIG are sometimes initiated before confirmatory testing returns when clinical suspicion is high.
Reported regimens vary; common adult dosing uses a loading bolus of 1.5–3 mg/kg followed by a continuous infusion titrated up to several mg/kg/hour. Ketamine is typically added rather than substituted, used in combination with midazolam or propofol. Hemodynamic effects favor ketamine in shocked patients but caution is warranted in those with elevated intracranial pressure or cardiovascular disease.
Evidence Grade & Bottom Line
Evidence Grade: Strong (for benzodiazepine first-line and second-line agent equivalence) / Moderate (for anesthetic phase) / Limited (for super-refractory therapies). Multiple high-quality RCTs anchor early-phase management. Observational evidence dominates refractory and super-refractory phases, where randomized comparisons remain operationally challenging.
Bottom Line
- Adequate-dose benzodiazepines within 5–20 minutes are the single highest-yield intervention; under-dosing remains the most preventable cause of progression.
- ESETT establishes that fosphenytoin, valproate, and levetiracetam are equivalent as second-line agents; selection should be driven by patient comorbidities and local protocols.
- Refractory status epilepticus requires anesthetic infusion in the ICU with continuous EEG monitoring, titrated to electrographic seizure cessation.
- Ketamine has growing observational support as an adjunct in refractory and super-refractory cases, particularly when GABAergic agents alone have failed.
- Etiology and age dominate the prognostic landscape; choice of antiseizure agent has not been shown to alter mortality independent of the underlying cause.
Article Information & References
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Kapur J, Elm J, Chamberlain JM, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. New England Journal of Medicine. 2019;381(22):2103-2113. DOI: 10.1056/NEJMoa1905795
- Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus. New England Journal of Medicine. 2012;366(7):591-600. DOI: 10.1056/NEJMoa1107494
- Treiman DM, Meyers PD, Walton NY, et al. A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus. New England Journal of Medicine. 1998;339(12):792-798. DOI: 10.1056/NEJM199809173391202
- Alldredge BK, Gelb AM, Isaacs SM, et al. A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus. New England Journal of Medicine. 2001;345(9):631-637. DOI: 10.1056/NEJMoa002141
- Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults. Epilepsy Currents. 2016;16(1):48-61. DOI: 10.5698/1535-7597-16.1.48
- Brophy GM, Bell R, Claassen J, et al. Guidelines for the Evaluation and Management of Status Epilepticus. Neurocritical Care. 2012;17(1):3-23. DOI: 10.1007/s12028-012-9695-z
- Trinka E, Cock H, Hesdorffer D, et al. A Definition and Classification of Status Epilepticus — Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523. DOI: 10.1111/epi.13121
- Gaspard N, Foreman B, Judd LM, et al. Intravenous Ketamine for the Treatment of Refractory Status Epilepticus: A Retrospective Multicenter Study. Epilepsia. 2013;54(8):1498-1503. DOI: 10.1111/epi.12247
- Rosati A, L’Erario M, Ilvento L, et al. Efficacy and Safety of Ketamine in Refractory Status Epilepticus in Children. Neurology. 2012;79(24):2355-2358. DOI: 10.1212/WNL.0b013e318278b685
- Hocker SE, Britton JW, Mandrekar JN, et al. Predictors of Outcome in Refractory Status Epilepticus. JAMA Neurology. 2013;70(1):72-77. DOI: 10.1001/jamaneurol.2013.578
- Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and Prognosis of Refractory Status Epilepticus Treated in a Neurological Intensive Care Unit. Journal of Neurology, Neurosurgery, and Psychiatry. 2005;76(4):534-539. DOI: 10.1136/jnnp.2004.041947
- Shorvon S, Ferlisi M. The Treatment of Super-Refractory Status Epilepticus: A Critical Review of Available Therapies and a Clinical Treatment Protocol. Brain. 2011;134(Pt 10):2802-2818. DOI: 10.1093/brain/awr215
- Legriel S, Lemiale V, Schenck M, et al. Hypothermia for Neuroprotection in Convulsive Status Epilepticus (HYBERNATUS). New England Journal of Medicine. 2016;375(25):2457-2467. DOI: 10.1056/NEJMoa1608193